新基因HA117在儿童急性白血病中的表达及其临床意义

Clinical Significance of HA117 Expression in Children with Acute Leukemia

目的检测新基因HA117在急性白血病(AL)患儿骨髓单个核细胞(BMMNC)中的表达,并探讨其与多药耐药关系。方法应用RT-PCR方法检测36例不同时期AL患儿BMMNC HA117基因的表达;以10例特发性血小板减少性紫癜(ITP)患儿作为对照。结果36例AL患儿BMMNC HA117基因阳性表达率为75.00%,急性淋巴细胞白血病(ALL)组其阳性表达率(69.57%)与急性髓细胞白血病(AML)组(91.67%)比较差异无统计学意义。但AML组HA117/β-actin定量表达水平高于ALL组(q=4.5852,P<0.01)。AML组和ALL组HA117基因阳性表达率及HA117/β-actin定量表达水平均高于对照组(χ2=5.05,8.81;q=4.4612,6.9695,P<0.05)。初诊组患儿BMMNC HA117基因阳性表达率(72.00%)高于对照组(χ2=5.91,P<0.05),与缓解组患儿(77.78%)比较差异无统计学意义。初诊组HA117/β-actin定量表达水平高于缓解组和对照组(q=5.1991,6.3812,P<0.01)。缓解组HA117基因阳性表达率高于对照组(χ2=4.24,P<0.05),但其半定量表达水平与对照组比较差异无统计学意义。未缓解组HA117/β-actin定量表达水平高于缓解组和对照组(q=3.1705,4.4102;P<0.05),与初诊组比较差异无统计学意义。结论新基因HA117在初诊和未缓解AL患儿BMMNC中具有高表达。HA117可能参与了白血病的多药耐药,临床以HA117基因半定量检测更有意义。

Objective To explore the role of the expression of HA117 gene in bone marrow mononuclear cells （BMMNC） with acute leukemia and multidrug resistance. Methods HA117 gene expressions in 36 children with acute leukemia and 10 children with Idiopathic thrombocytopenic purpura （ITP） were tested using semi quantitative reverse transcriptase polymerase chain reaction （RT-PCR） technique. Results The HA117 gene was expressed in 75% of children with acute leukemia. There was no significant difference in HA117 gene expression between children with acute lymphoblastic leukemia （ALL, 69. 57%） and children with acute myeloid leukemia （AML, 91.67 %）. But the semi-quantitative expression of HA117/β-actin in AML childern was significantly higher than in ALL children （q=4. 5852, P〈0.01）. The expressions of HA117 gene and HA117/β-actin in both ALL and AML children were significantly higher than in ITP children （χ^2 -= 5.05,8.81; q= 4. 4612,6. 9695; P〈0.05）. The remission patients had lower expression of HA117/β-actin and similar expression of HA117 compared with initially diagnosed patients, The remission patients had higher expression of HA117 gene and similar expression of HA117/ β-actin compared with patients with ITP. The non-remission patients had higher expression of HA117/β-actin than remission patients and ITP patients （q= 3. 1705,4. 4102, P〈0.05）, but no significant difference from initially diagnosed patients （q=0. 5470,P〉0.05）. Conclusion The expression of HA117 gene is high in the BMMNC of initially diagnosed and non-remission patients with AL. But the remission patients have similar semi-quantitative expression of HA117 as patients with ITP, which indicates that a quantitative testing is more important. The expression of HA117 gene decreases with the improvement of the illness. HA117 is one of the factors that may affect the clinical remission of AML, The new gene HA117 may also he associated with multidrug resistance of leukemia.